February 9, 2004
Dr. Walker then presented the longitudinal data for a total of 14 patients (all had acute retroviral syndrome) followed for an average of 5.3 years including for up to 3 years after the last STI. Only 1/14 of the patients has maintained control of viremia (defined as <5,000 copies RNA/mL). The second and third STI failed more quickly, with the fourth STI providing no observable benefit.
The rate of CD4 count loss when antiretroviral therapy was stopped was quite high and it was not much different from the CD4 loss observed when stopping antiretroviral therapy in the setting of chronic infection. Dr. Walker then discussed what factors could be identified that could predict the control of viremia. They had looked at HLA type, CCR5 status, GBV-C infection, time of treatment since onset of antiretroviral syndrome (ARS) symptoms, viral load at seroconversion, and anti-HIV immunity from CD4+ or CD8+ T-cells. None of those factors predicted control of viral rebound.
Particularly disappointing was the observation that, although anti-HIV immunity appeared to be enhanced with the STIs, this did not translate into observable clinical benefit. These results were interpreted to indicate that durable maintenance of low-level viremia may be difficult to achieve. The CD4 declines were substantial with immune escape at even low viral loads sufficient to be a problem.
In a question to Dr. Walker, Joe Eron made the comment that the window to perhaps protect anti-HIV immunity during primary infection may be vanishingly short. Another questioner pointed out that the definition of failure (confirmed viral load >5,000 copies/mL or one viral load >50,000) made it difficult to perhaps see some attenuation in the true magnitude of viral rebound. Although Dr. Walker stated that randomized clinical trials of early treatment and immune interventions are needed, the enthusiasm about the potential for this to achieve much has waned.
In all, the different presentations on acute infection suggested that we can do much better in finding and preventing recent infections. Although discussed a lot, superinfections still seem to be relatively unusual but are a growing problem. And it's still unclear how helpful treatment during acute infection is.
Abstract: Limited Durability of Immune Control Following Treated Acute HIV Infection (Oral 24)
Authored by: D. Kaufmann, M. Lichterfeld, M. Altfeld, T. Allen, M. Johnston, P. Lee, B. Wagner, E. Kalife, D. Strick, E. Rosenberg, B. D. Walker
Affiliations: Partners AIDS Res. Ctr., Massachusetts Gen. Hosp., Boston, MA; Howard Hughes Med. Inst.
|Please note: Knowledge about HIV changes rapidly. Note the date of this summary's publication, and before treating patients or employing any therapies described in these materials, verify all information independently. If you are a patient, please consult a doctor or other medical professional before acting on any of the information presented in this summary. For a complete listing of our most recent conference coverage, click here.|